FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3034853086> ?p ?o ?g. }

• W3034853086 endingPage "910" @default.
• W3034853086 startingPage "900" @default.
• W3034853086 abstract "Abstract Background Candidaemia is an important infectious complication for haematological malignancy patients. Antifungal prophylaxis reduces the incidence of candidaemia but may be associated with breakthrough candidaemia. Objective To analyse the Candida species’ distribution and relative antifungal susceptibility profiles of candidaemia episodes in relation to the use of antifungal prophylaxis among Italian SEIFEM haematology centres. Methodology This multicentre retrospective observational SEIFEM study included 133 single‐species candidaemia episodes of haematological malignancy patients for whom antifungal susceptibility testing results of blood Candida isolates were available between 2011 and 2015. Each participating centre provided both clinical and microbiological data. Results Non‐ Candida albicans Candida (NCAC) species were the mostly isolated species (89, 66.9%), which accounted for C parapsilosis (35, 26.3%), C glabrata (16, 12.0%), C krusei (14, 10.5%), C tropicalis (13, 9.8%) and uncommon species (11, 8.3%). C albicans caused the remaining 44 (33.1%) episodes. Excluding 2 C albicans isolates, 23 of 25 fluconazole‐resistant isolates were NCAC species (14 C krusei , 6 C glabrata , 2 C parapsilosis and 1 C tropicalis ). Fifty‐six (42.1%) of 133 patients developed breakthrough candidaemia. Systemic antifungal prophylaxis consisted of azoles, especially fluconazole and posaconazole, in 50 (89.3%) of 56 patients in whom a breakthrough candidaemia occurred. Interestingly, all these patients tended to develop a C krusei infection (10/56, P = .02) or a fluconazole‐resistant isolate’s infection (14/50, P = .04) compared to patients (4/77 and 10/77, respectively) who did not have a breakthrough candidaemia. Conclusions Optimisation of prophylactic strategies is necessary to limit the occurrence of breakthrough candidaemia and, importantly, the emergence of fluconazole‐resistant NCAC isolates’ infections in haematological malignancy patients." @default.
• W3034853086 created "2020-06-19" @default.
• W3034853086 creator A5003132589 @default.
• W3034853086 creator A5003619706 @default.
• W3034853086 creator A5012932458 @default.
• W3034853086 creator A5014371750 @default.
• W3034853086 creator A5040794664 @default.
• W3034853086 creator A5046702889 @default.
• W3034853086 creator A5053160212 @default.
• W3034853086 creator A5053181448 @default.
• W3034853086 creator A5056830531 @default.
• W3034853086 creator A5058077100 @default.
• W3034853086 creator A5059488532 @default.
• W3034853086 creator A5061887463 @default.
• W3034853086 creator A5077541772 @default.
• W3034853086 creator A5079012854 @default.
• W3034853086 creator A5084331370 @default.
• W3034853086 creator A5089427293 @default.
• W3034853086 date "2020-07-03" @default.
• W3034853086 modified "2023-10-01" @default.
• W3034853086 title "Candidaemia in haematological malignancy patients from a SEIFEM study: Epidemiological patterns according to antifungal prophylaxis" @default.
• W3034853086 cites W1605806048 @default.
• W3034853086 cites W1653248413 @default.
• W3034853086 cites W1800819261 @default.
• W3034853086 cites W1909349784 @default.
• W3034853086 cites W1942573227 @default.
• W3034853086 cites W1945274605 @default.
• W3034853086 cites W1978501793 @default.
• W3034853086 cites W1984762334 @default.
• W3034853086 cites W1988218622 @default.
• W3034853086 cites W2002991991 @default.
• W3034853086 cites W2018917176 @default.
• W3034853086 cites W2026729241 @default.
• W3034853086 cites W2056259693 @default.
• W3034853086 cites W2062983075 @default.
• W3034853086 cites W2069678662 @default.
• W3034853086 cites W2075066076 @default.
• W3034853086 cites W2080906582 @default.
• W3034853086 cites W2089758421 @default.
• W3034853086 cites W2109148349 @default.
• W3034853086 cites W2109814431 @default.
• W3034853086 cites W2124878837 @default.
• W3034853086 cites W2140866323 @default.
• W3034853086 cites W2157819004 @default.
• W3034853086 cites W2159872511 @default.
• W3034853086 cites W2221562130 @default.
• W3034853086 cites W2443286287 @default.
• W3034853086 cites W2598422593 @default.
• W3034853086 cites W2739253973 @default.
• W3034853086 cites W2751235145 @default.
• W3034853086 cites W2773217499 @default.
• W3034853086 cites W2781712060 @default.
• W3034853086 cites W2906643351 @default.
• W3034853086 cites W2912130549 @default.
• W3034853086 cites W2919717710 @default.
• W3034853086 cites W2922388167 @default.
• W3034853086 cites W2932341513 @default.
• W3034853086 cites W2999861607 @default.
• W3034853086 cites W4253534765 @default.
• W3034853086 doi "https://doi.org/10.1111/myc.13130" @default.
• W3034853086 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32531854" @default.
• W3034853086 hasPublicationYear "2020" @default.
• W3034853086 type Work @default.
• W3034853086 sameAs 3034853086 @default.
• W3034853086 citedByCount "9" @default.
• W3034853086 countsByYear W30348530862021 @default.
• W3034853086 countsByYear W30348530862022 @default.
• W3034853086 countsByYear W30348530862023 @default.
• W3034853086 crossrefType "journal-article" @default.
• W3034853086 hasAuthorship W3034853086A5003132589 @default.
• W3034853086 hasAuthorship W3034853086A5003619706 @default.
• W3034853086 hasAuthorship W3034853086A5012932458 @default.
• W3034853086 hasAuthorship W3034853086A5014371750 @default.
• W3034853086 hasAuthorship W3034853086A5040794664 @default.
• W3034853086 hasAuthorship W3034853086A5046702889 @default.
• W3034853086 hasAuthorship W3034853086A5053160212 @default.
• W3034853086 hasAuthorship W3034853086A5053181448 @default.
• W3034853086 hasAuthorship W3034853086A5056830531 @default.
• W3034853086 hasAuthorship W3034853086A5058077100 @default.
• W3034853086 hasAuthorship W3034853086A5059488532 @default.
• W3034853086 hasAuthorship W3034853086A5061887463 @default.
• W3034853086 hasAuthorship W3034853086A5077541772 @default.
• W3034853086 hasAuthorship W3034853086A5079012854 @default.
• W3034853086 hasAuthorship W3034853086A5084331370 @default.
• W3034853086 hasAuthorship W3034853086A5089427293 @default.
• W3034853086 hasConcept C120665830 @default.
• W3034853086 hasConcept C121332964 @default.
• W3034853086 hasConcept C126322002 @default.
• W3034853086 hasConcept C145081991 @default.
• W3034853086 hasConcept C2775835631 @default.
• W3034853086 hasConcept C2777071850 @default.
• W3034853086 hasConcept C2778566413 @default.
• W3034853086 hasConcept C2779443200 @default.
• W3034853086 hasConcept C2779548794 @default.
• W3034853086 hasConcept C2780651595 @default.
• W3034853086 hasConcept C2780670043 @default.
• W3034853086 hasConcept C2780917455 @default.
• W3034853086 hasConcept C2781425774 @default.

• next